Data presented at the 2016 annual meeting of the American Society of Clinical Oncology have revealed mixed findings when bevacizumab is added to conventional chemotherapy for the treatment of pediatric soft tissue sarcoma (abstract 11054). On one hand, researchers found the combination increased the likelihood of clinical response and lengthened the duration of event-free survival, but on the other, it was also associated with a nonsignificant shorter duration of overall survival than
JULY 29, 2016